Dr. Koos Stiekema was was sued by the pharmaceutical company Organon for violating his confidentiality agreement after discussing his concerns with three ethics committees that the lowest dose of the drug pentasaccharide being tested in patients with acute coronary syndrome would not be sufficient to prevent myocardial infarctions.
Dr. Koos Stiekema was was sued by the pharmaceutical company Organon for violating his confidentiality agreement after discussing his concerns about a clinical trial design with three ethics committees. The trial was designed to examine the use of a synthetic pentasaccharide to treat patients with acute coronary syndrome, and Dr. Stiekema was concerned that lowest of the four doses being examined would not be sufficient to prevent myocardial infarctions.